Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ondrej Fiala

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Pathology International|January 11, 2026
KIM-1: From Prognostic Indicator to Therapeutic Stratification Tool in Adjuvant Renal Cell CarcinomaKannan Sridharan, Ondrej Fiala, Matteo Santoni
Nature Reviews. Urology|September 6, 2024
Non-coding transcriptome profiles in clear-cell renal cell carcinomaTereza Tesarova, Ondrej Fiala, Milan Hora, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|September 28, 2020
Octreotide in the treatment of malignant thymoma - Case reportOndrej Sorejs, Milos Pesek, Jindrich Finek, et al.
Sports Medicine and Health Science|April 23, 2025
Beyond physical exhaustion: Understanding overtraining syndrome through the lens of molecular mechanisms and clinical manifestationOndrej Fiala, Michaela Hanzlova, Lenka Borska, et al.
Tumori|July 31, 2014
Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case reportOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Cancer Genetics|January 15, 2013
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|July 31, 2013
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequenceOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|April 9, 2013
Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacyOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|March 6, 2020
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint InhibitorsOndrej Fiala, Ondrej Sorejs, Jan Sustr, et al.
Cancers|November 27, 2019
Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 PatientsOndrej Fiala, Pavel Ostasov, Ondrej Sorejs, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Pathology International|January 11, 2026
KIM-1: From Prognostic Indicator to Therapeutic Stratification Tool in Adjuvant Renal Cell CarcinomaKannan Sridharan, Ondrej Fiala, Matteo Santoni
Nature Reviews. Urology|September 6, 2024
Non-coding transcriptome profiles in clear-cell renal cell carcinomaTereza Tesarova, Ondrej Fiala, Milan Hora, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|September 28, 2020
Octreotide in the treatment of malignant thymoma - Case reportOndrej Sorejs, Milos Pesek, Jindrich Finek, et al.
Sports Medicine and Health Science|April 23, 2025
Beyond physical exhaustion: Understanding overtraining syndrome through the lens of molecular mechanisms and clinical manifestationOndrej Fiala, Michaela Hanzlova, Lenka Borska, et al.
Tumori|July 31, 2014
Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case reportOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Cancer Genetics|January 15, 2013
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|July 31, 2013
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequenceOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|April 9, 2013
Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacyOndrej Fiala, Milos Pesek, Jindrich Finek, et al.
Anticancer Research|March 6, 2020
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint InhibitorsOndrej Fiala, Ondrej Sorejs, Jan Sustr, et al.
Cancers|November 27, 2019
Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 PatientsOndrej Fiala, Pavel Ostasov, Ondrej Sorejs, et al.
Pageof 10